Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide

R. A. Joss, P. Alberto, J. P. Obrecht, L. Barrelet, E. E. Holdener, P. Siegenthaler, A. Goldhirsch, B. Mermillod, F. Cavalli

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The combinations of doxorubicin (40 mg/m2 iv every 3 weeks) and mitomycin (12 mg/m2 iv every 6 weeks) or cisplatin (80 mg/m2 iv every 3 weeks x 3, then every 6 weeks) and etoposide (80 mg/m2 iv on Days 1-3 every 3 weeks x 3, then every 6 weeks) were evaluated in a randomized phase II trial in 77 patients with measurable or evaluable non-small cell lung cancer. No patient had been pretreated with prior chemotherapy. The overall response rate for the doxorubicin and mitomycin regimen was 11% and for the cisplatin and etoposide regimen was 23%. Responses lasted a median of 5.5 months. Median survival was 7.0 months for the doxorubicin and mitomycin regimen and 8.0 months for the cisplatin and etoposide regimen. One treatment-related death was observed after doxorubicin and mitomycin in a patient who had received radiation therapy immediately prior to study entry. Otherwise, the hematologic toxicity of both chemotherapy regimens was moderate, with only six patients (10%) having World Health Organization grade 3 toxicity and no patients having World Health Organization grade 4 toxicity. However, subjective tolerance (gastrointestinal upset) of the cisplatin and etoposide combination was poor.

Original languageEnglish
Pages (from-to)1079-1084
Number of pages6
JournalCancer Treatment Reports
Volume68
Issue number9
Publication statusPublished - 1984

Fingerprint

Mitomycin
Etoposide
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Doxorubicin
Cisplatin
Drug Therapy
Radiotherapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Joss, R. A., Alberto, P., Obrecht, J. P., Barrelet, L., Holdener, E. E., Siegenthaler, P., ... Cavalli, F. (1984). Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide. Cancer Treatment Reports, 68(9), 1079-1084.

Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide. / Joss, R. A.; Alberto, P.; Obrecht, J. P.; Barrelet, L.; Holdener, E. E.; Siegenthaler, P.; Goldhirsch, A.; Mermillod, B.; Cavalli, F.

In: Cancer Treatment Reports, Vol. 68, No. 9, 1984, p. 1079-1084.

Research output: Contribution to journalArticle

Joss, RA, Alberto, P, Obrecht, JP, Barrelet, L, Holdener, EE, Siegenthaler, P, Goldhirsch, A, Mermillod, B & Cavalli, F 1984, 'Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide', Cancer Treatment Reports, vol. 68, no. 9, pp. 1079-1084.
Joss RA, Alberto P, Obrecht JP, Barrelet L, Holdener EE, Siegenthaler P et al. Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide. Cancer Treatment Reports. 1984;68(9):1079-1084.
Joss, R. A. ; Alberto, P. ; Obrecht, J. P. ; Barrelet, L. ; Holdener, E. E. ; Siegenthaler, P. ; Goldhirsch, A. ; Mermillod, B. ; Cavalli, F. / Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide. In: Cancer Treatment Reports. 1984 ; Vol. 68, No. 9. pp. 1079-1084.
@article{93cdb766099a4625a042a6181430e4f0,
title = "Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide",
abstract = "The combinations of doxorubicin (40 mg/m2 iv every 3 weeks) and mitomycin (12 mg/m2 iv every 6 weeks) or cisplatin (80 mg/m2 iv every 3 weeks x 3, then every 6 weeks) and etoposide (80 mg/m2 iv on Days 1-3 every 3 weeks x 3, then every 6 weeks) were evaluated in a randomized phase II trial in 77 patients with measurable or evaluable non-small cell lung cancer. No patient had been pretreated with prior chemotherapy. The overall response rate for the doxorubicin and mitomycin regimen was 11{\%} and for the cisplatin and etoposide regimen was 23{\%}. Responses lasted a median of 5.5 months. Median survival was 7.0 months for the doxorubicin and mitomycin regimen and 8.0 months for the cisplatin and etoposide regimen. One treatment-related death was observed after doxorubicin and mitomycin in a patient who had received radiation therapy immediately prior to study entry. Otherwise, the hematologic toxicity of both chemotherapy regimens was moderate, with only six patients (10{\%}) having World Health Organization grade 3 toxicity and no patients having World Health Organization grade 4 toxicity. However, subjective tolerance (gastrointestinal upset) of the cisplatin and etoposide combination was poor.",
author = "Joss, {R. A.} and P. Alberto and Obrecht, {J. P.} and L. Barrelet and Holdener, {E. E.} and P. Siegenthaler and A. Goldhirsch and B. Mermillod and F. Cavalli",
year = "1984",
language = "English",
volume = "68",
pages = "1079--1084",
journal = "Cancer Treatment Reports",
issn = "0361-5960",
publisher = "U.S. National Cancer Institute",
number = "9",

}

TY - JOUR

T1 - Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide

AU - Joss, R. A.

AU - Alberto, P.

AU - Obrecht, J. P.

AU - Barrelet, L.

AU - Holdener, E. E.

AU - Siegenthaler, P.

AU - Goldhirsch, A.

AU - Mermillod, B.

AU - Cavalli, F.

PY - 1984

Y1 - 1984

N2 - The combinations of doxorubicin (40 mg/m2 iv every 3 weeks) and mitomycin (12 mg/m2 iv every 6 weeks) or cisplatin (80 mg/m2 iv every 3 weeks x 3, then every 6 weeks) and etoposide (80 mg/m2 iv on Days 1-3 every 3 weeks x 3, then every 6 weeks) were evaluated in a randomized phase II trial in 77 patients with measurable or evaluable non-small cell lung cancer. No patient had been pretreated with prior chemotherapy. The overall response rate for the doxorubicin and mitomycin regimen was 11% and for the cisplatin and etoposide regimen was 23%. Responses lasted a median of 5.5 months. Median survival was 7.0 months for the doxorubicin and mitomycin regimen and 8.0 months for the cisplatin and etoposide regimen. One treatment-related death was observed after doxorubicin and mitomycin in a patient who had received radiation therapy immediately prior to study entry. Otherwise, the hematologic toxicity of both chemotherapy regimens was moderate, with only six patients (10%) having World Health Organization grade 3 toxicity and no patients having World Health Organization grade 4 toxicity. However, subjective tolerance (gastrointestinal upset) of the cisplatin and etoposide combination was poor.

AB - The combinations of doxorubicin (40 mg/m2 iv every 3 weeks) and mitomycin (12 mg/m2 iv every 6 weeks) or cisplatin (80 mg/m2 iv every 3 weeks x 3, then every 6 weeks) and etoposide (80 mg/m2 iv on Days 1-3 every 3 weeks x 3, then every 6 weeks) were evaluated in a randomized phase II trial in 77 patients with measurable or evaluable non-small cell lung cancer. No patient had been pretreated with prior chemotherapy. The overall response rate for the doxorubicin and mitomycin regimen was 11% and for the cisplatin and etoposide regimen was 23%. Responses lasted a median of 5.5 months. Median survival was 7.0 months for the doxorubicin and mitomycin regimen and 8.0 months for the cisplatin and etoposide regimen. One treatment-related death was observed after doxorubicin and mitomycin in a patient who had received radiation therapy immediately prior to study entry. Otherwise, the hematologic toxicity of both chemotherapy regimens was moderate, with only six patients (10%) having World Health Organization grade 3 toxicity and no patients having World Health Organization grade 4 toxicity. However, subjective tolerance (gastrointestinal upset) of the cisplatin and etoposide combination was poor.

UR - http://www.scopus.com/inward/record.url?scp=0021186055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021186055&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 1079

EP - 1084

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 9

ER -